z-logo
open-access-imgOpen Access
Bone marrow‐derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition
Author(s) -
Pietrovito Laura,
Leo Angela,
Gori Valentina,
Lulli Matteo,
Parri Matteo,
Becherucci Valentina,
Piccini Luisa,
Bambi Franco,
Taddei Maria Letizia,
Chiarugi Paola
Publication year - 2018
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12189
Subject(s) - mesenchymal stem cell , microbiology and biotechnology , biology , bone marrow , stromal cell , stem cell , cancer research , cytokine , immunology
There is growing evidence to suggest that bone marrow‐derived mesenchymal stem cells ( BM ‐ MSC s) are key players in tumour stroma. Here, we investigated the cross‐talk between BM ‐ MSC s and osteosarcoma ( OS ) cells. We revealed a strong tropism of BM ‐ MSC s towards these tumour cells and identified monocyte chemoattractant protein ( MCP )‐1, growth‐regulated oncogene ( GRO )‐α and transforming growth factor ( TGF )‐β1 as pivotal factors for BM ‐ MSC chemotaxis. Once in contact with OS cells, BM ‐ MSC s trans‐differentiate into cancer‐associated fibroblasts, further increasing MCP ‐1, GRO ‐α, interleukin ( IL )‐6 and IL ‐8 levels in the tumour microenvironment. These cytokines promote mesenchymal to amoeboid transition ( MAT ), driven by activation of the small GTP ase RhoA, in OS cells, as illustrated by the in vitro assay and live imaging. The outcome is a significant increase of aggressiveness in OS cells in terms of motility, invasiveness and transendothelial migration. In keeping with their enhanced transendothelial migration abilities, OS cells stimulated by BM ‐ MSC s also sustain migration, invasion and formation of the in vitro capillary network of endothelial cells. Thus, BM ‐ MSC recruitment to the OS site and the consequent cytokine‐induced MAT are crucial events in OS malignancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here